Lunai Bioworks Inc. (LNAI) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
↓
-321.8%
↑-171% vs avg
5yr avg: -118.9%
30Y Low-322%·High-15%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LNAI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lunai Bioworks Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $20M | — | — | — | — | — |
| Enterprise Value | $30M | — | — | — | — | — |
| P/E Ratio → | -0.05 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LNAI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
LNAI Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -321.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -321.8% | -321.8% | -99.1% | -66.6% | -91.7% | -15.3% |
| ROA | -207.8% | -207.8% | -79.9% | -55.5% | -82.7% | -14.1% |
| ROIC | -22.4% | -22.4% | -65.9% | -47.9% | -75.1% | -10.9% |
| ROCE | -33.2% | -33.2% | -90.7% | -61.5% | -87.3% | -12.5% |
LNAI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $10M ($10M total debt minus $92700 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.03 | 0.12 | 0.10 | 0.04 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 0.03 | 0.08 | -0.03 | -0.08 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -244.30 | -244.30 | -35.32 | -55.13 | -303.24 | -69.73 |
LNAI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.04x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.23x to 0.04x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.04 | 0.04 | 0.07 | 0.23 | 1.48 | 11.08 |
| Quick Ratio | 0.04 | 0.04 | 0.07 | 0.23 | 1.48 | 11.08 |
| Cash Ratio | 0.02 | 0.02 | 0.01 | 0.17 | 1.42 | 10.96 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
LNAI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lunai Bioworks Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $2M | $1M | $703317 | $656600 | $589591 |
Peer Comparison
Compare LNAI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LNAIYou | $20M | -0.1 | — | — | — | — | -321.8% | -22.4% | — |
 BEAM | $3B | -41.0 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 TWST | $5B | -65.4 | — | — | 50.7% | -36.2% | -16.4% | -26.9% | — |
 CDNA | $1B | -62.8 | — | 35.9 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 SRPT | $2B | -2.4 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 NTLA | $2B | -4.0 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -8.3 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $270M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 ILMN | $25B | 30.3 | 23.1 | 26.9 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $174B | 26.5 | 18.9 | 27.7 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $127B | 35.5 | 18.5 | 24.1 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
| Healthcare Median | — | 22.0 | 14.1 | 18.7 | 63.6% | -4.8% | -32.4% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
LNAI — Frequently Asked Questions
Quick answers to the most common questions about buying LNAI stock.
What is Lunai Bioworks Inc.'s P/E ratio?
Lunai Bioworks Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Lunai Bioworks Inc.'s ROE?
Lunai Bioworks Inc.'s return on equity (ROE) is -321.8%. The historical average is -118.9%.
Is LNAI stock overvalued?
Based on historical data, Lunai Bioworks Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.